Insider · CIK 0001936604
Lindsay Androski
directorceopresidentofficer
Files at ELOX (Eloxx Pharmaceuticals, Inc.), ABUS (Arbutus Biopharma Corp). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | ABUS Arbutus Biopharma Corp | DDisposition to issuer Common Shares | -24,655 | $5.00 | $123k | 47,682 | 5 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Common Shares | +116,408 | $3.20 | $373k | 144,408 | 19 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Common Shares | +10,456 | $4.39 | $46k | 154,864 | 19 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | FTax withholding Common Shares | -82,527 | $5.07 | $418k | 72,337 | 19 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Stock Option (Right to Buy)derivative | -116,408 | $0.00 | $0 | 194,014 | 19 d ago |
| Sep 18, 2026 | ABUS Arbutus Biopharma Corp | MOption exercise Stock Option (Right to Buy)derivative | -10,456 | $0.00 | $0 | 61,244 | 19 d ago |
| Feb 2, 2026 | ABUS Arbutus Biopharma Corp | AGrant or award Common Shares | +28,000 | $0.00 | $0 | 28,000 | Feb 2, 2026 |
| Feb 2, 2026 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +71,700 | $0.00 | $0 | 71,700 | Feb 2, 2026 |
| Mar 18, 2025 | ABUS Arbutus Biopharma Corp | AGrant or award Stock Option (Right to Buy)derivative | +310,422 | $0.00 | $0 | 310,422 | Mar 20, 2025 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Common Stock | +3,750 | $0.00 | $0 | 15,750 | Jan 28, 2025 |
| Jan 24, 2025 | ELOX Eloxx Pharmaceuticals, Inc. | MOption exercise Restricted Stock Unitsderivative | -3,750 | $0.00 | $0 | 3,750 | Jan 28, 2025 |
| Oct 16, 2024 | ELOX Eloxx Pharmaceuticals, Inc. | AGrant or award Common Stock | +12,000 | $0.00 | $0 | 12,000 | Oct 17, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.